Highlights Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
5.84 ^USD	+1.57%		-0.51%	+30.94%

07/05	Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	MT
07/05	Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	08/05	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	19/04	DJ
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	19/04	MT
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	18/04	CI
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	06/04	CI
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours	12/03	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q4 Revenue $14.8M, vs. Street Est of $15.7M	12/03	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03	CI
North American Morning Briefing : Stock Futures -2-	11/03	DJ
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA	19/02	CI
Ocular Therapeutix, Inc. Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of Axpaxli in Wet Amd	13/02	CI
Ocular Therapeutix Shares Rise as US FDA Modifies Enrollment Criteria, Drug Dosage for Axitinib Pivotal Study	25/01	MT
Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment for Pivotal Clinical Trial of Axpaxli in Wet AMD	25/01	CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q3 Revenue $15.1M	08/11	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023	08/11	CI
Ocular Therapeutix to Start Patient Enrollment for Wet AMD Trial; Shares Gain	01/11	MT
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD	01/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Highlights

Filters